Gil Beyen, chief executive of Erytech Pharma SA, has joined the board of directors of Novadip Biosciences SA, a regenerative medicine company spun out of the University of Louvain in Belgium. Novadip’s first product is an autologous cell-based therapy for the repair of skeletal tissue. Prior to joining Erytech, Mr Beyen was co-founder and chief executive of TiGenix SA, the first company to get approval for a cell therapy in Europe. This is a product for the repair of cartilage defects in the knee.
Mr Beyen holds an MSc in bioengineering from the University of Leuven and a master’s in business administration from the University of Chicago in the US.
Novadip Biosciences announced the appointment on 15 December 2014.
Copyright 2014 Evernow Publishing Ltd